person · Reporting owner
LONGENECKER JOHN P PHD
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | March 03, 2022 | March 07, 2022 |
| Rein Therapeutics, Inc.ALRN · Entity 7071 | President and CEO | August 10, 2018 | August 14, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date March 03, 2022 · Filed March 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,823 |
Ending reported balance
After 2022-03-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-03 · Exercise / conversion · Acquired 7,000 · Balance 25,823 Row 2 · 2022-03-03 · Sale · Disposed 7,000 · Balance 18,823 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2022-06-04 | Direct | 0 |
Reported balance
After 2022-03-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-03 · Exercise / conversion · Disposed 7,000 · Balance 0 F1: The stock option vested and became exercisable in twelve equal monthly installments, with the first installment being on July 5, 2012. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vested and became exercisable in twelve equal monthly installments, with the first installment being on July 5, 2012.
Rein Therapeutics, Inc.
Report date August 10, 2018 · Filed August 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2018-08-10 transaction · row 1
1 source rowRow 1 · 2018-08-10 · Purchase · Acquired 10,000 · Balance 10,000 F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.40 to $2.48, inclusive. The reporting person undertakes to provide to Aileron Therapeutics, Inc., any security holder of Aileron Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.40 to $2.48, inclusive. The reporting person undertakes to provide to Aileron Therapeutics, Inc., any security holder of Aileron Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2022 Filed Mar 7, 2022 20:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-22-016873 · doc4.xml · derivative · entry 3 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested and became exercisable in twelve equal monthly installments, with the first installment being on July 5, 2012. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 20:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 7,000 | $71.74 | $502,145.00 |
DisclosureSEC source: 0001209191-22-016873 · doc4.xml · nonDerivative · entry 2 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,823 Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 20:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 7,000 | $10.81 | $75,670.00 |
DisclosureSEC source: 0001209191-22-016873 · doc4.xml · nonDerivative · entry 1 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 7,626 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0001209191-21-040087 · doc4.xml · derivative · entry 2 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,626 Underlying: Common Stock · 7,626 shares Expires 2031-06-09 Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040087 · doc4.xml · nonDerivative · entry 1 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,823 F1 · shares: Represents restricted stock units that vest on June 3, 2022, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001209191-21-016859 · doc4.xml · derivative · entry 3 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in 12 equal monthly installments beginning on July 2, 2011. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 5,000 | $72.26 | $361,300.00 |
DisclosureSEC source: 0001209191-21-016859 · doc4.xml · nonDerivative · entry 2 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,757 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.95 to $72.71, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 5,000 | $13.98 | $69,900.00 |
DisclosureSEC source: 0001209191-21-016859 · doc4.xml · nonDerivative · entry 1 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 18:27 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 8,027 | $0.00 Strike: $47.65 | $0.00 |
DisclosureSEC source: 0001209191-20-036042 · doc4.xml · derivative · entry 2 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,027 Underlying: Common Stock · 8,027 shares Expires 2030-06-09 Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 18:27 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036042 · doc4.xml · nonDerivative · entry 1 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,757 F1 · shares: Represents restricted stock units that vest on June 3, 2021, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 17:53 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,736 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001209191-20-019347 · doc4.xml · derivative · entry 2 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,736 shares Expires 2020-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 75% of the options on September 2, 2010 and vested as to the remaining 25% of the options in successive equal monthly installments for the subsequent 12 months. The options became exercisable, to the extent vested, from and after the issuer's initial public offering. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 17:53 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 3,736 | $1.61 | $6,014.96 |
DisclosureSEC source: 0001209191-20-019347 · doc4.xml · nonDerivative · entry 1 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 16:46 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,128 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001209191-19-059089 · doc4.xml · derivative · entry 5 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,736 Underlying: Common Stock · 3,128 shares Expires 2020-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 75% of the options on September 2, 2010 and vested as to the remaining 25% of the options in successive equal monthly installments for the subsequent 12 months. The options became exercisable, to the extent vested, from and after the issuer's initial public offering. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 16:46 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 872 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001209191-19-059089 · doc4.xml · derivative · entry 4 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 872 shares Expires 2020-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 25% of the options on September 2, 2011 and vested as to the remaining options in successive equal monthly installments for the subsequent 36 months. The options became exercisable, to the extent vested, from and after the issuer's initial public offering. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 16:46 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,300 | $46.13 | $59,971.60 |
DisclosureSEC source: 0001209191-19-059089 · doc4.xml · nonDerivative · entry 3 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,761 Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 16:46 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 3,128 | $1.61 | $5,036.08 |
DisclosureSEC source: 0001209191-19-059089 · doc4.xml · nonDerivative · entry 2 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 16:46 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 872 | $1.61 | $1,403.92 |
DisclosureSEC source: 0001209191-19-059089 · doc4.xml · nonDerivative · entry 1 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 16:47 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 8,437 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-19-035108 · doc4.xml · derivative · entry 2 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,437 Underlying: Common Stock · 8,437 shares Expires 2029-06-05 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 16:47 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 4,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035108 · doc4.xml · nonDerivative · entry 1 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,061 F1 · shares: Represents restricted stock units that vest on June 3, 2020, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 23:38 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 10,000 | $2.45 | $24,500.00 |
DisclosureSEC source: 0000899243-18-022378 · doc4.xml · nonDerivative · entry 1 LONGENECKER JOHN P PHD · CIK 0001288231 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.40 to $2.48, inclusive. The reporting person undertakes to provide to Aileron Therapeutics, Inc., any security holder of Aileron Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 19:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 4,693 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-18-038196 · doc4.xml · derivative · entry 2 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,693 Underlying: Common Stock · 4,693 shares Expires 2028-06-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 19:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 782 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038196 · doc4.xml · nonDerivative · entry 1 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,927 F1 · shares: Represents restricted stock units that vest on June 3, 2019, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 15, 2018 Filed May 17, 2018 22:16 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000899243-18-013279 · doc4.xml · derivative · entry 1 LONGENECKER JOHN P PHD · CIK 0001288231 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-05-14 F1 · derivative.exercise_date: This option was granted on May 15, 2018. The shares underlying the option are scheduled to vest in full on the earlier of (i) September 15, 2018 or (ii) the date on which Dr. Longenecker's employment is terminated in connection with the Company's hiring of a new chief executive officer. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 2,714 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-17-040692 · doc4.xml · derivative · entry 2 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,714 Underlying: Common Stock · 2,714 shares Expires 2027-06-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040692 · doc4.xml · nonDerivative · entry 1 LONGENECKER JOHN P PHD · CIK 0001288231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,145 F1 · shares: Represents restricted stock units that vest on June 3, 2018, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.